{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T21:14:40Z","timestamp":1648847680436},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3,5]]},"DOI":"10.1097\/cm9.0000000000000042","type":"journal-article","created":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T00:02:21Z","timestamp":1551225741000},"page":"622-623","source":"Crossref","is-referenced-by-count":0,"title":["Beneficiality of combined levetiracetam, clonazepam for myoclonus in MERRF requires further confirmation"],"prefix":"10.1097","volume":"132","author":[{"given":"Josef","family":"Finsterer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-21-20210129","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.4103\/0366-6999.243568","article-title":"Antimyoclonic effect of levetiracetam and clonazepam combined treatment on myoclonic epilepsy with ragged-red fiber syndrome with m.8344A\u200a>\u200aG mutation","volume":"131","author":"Su","year":"2018","journal-title":"Chin Med J"},{"key":"R2-21-20210129","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1517\/17425255.2012.644535","article-title":"Mitochondrial toxicity of antiepileptic drugs and their tolerability in mitochondrial disorders","volume":"8","author":"Finsterer","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R3-21-20210129","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/lt.23965","article-title":"Acute liver failure after valproate exposure in patients with POLG1 mutations and the prognosis after liver transplantation","volume":"20","author":"Hynynen","year":"2014","journal-title":"Liver Transpl"},{"key":"R4-21-20210129","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.pediatrneurol.2017.12.005","article-title":"MERRF classification: implications for diagnosis and clinical trials","volume":"80","author":"Finsterer","year":"2018","journal-title":"Pediatr Neurol"},{"key":"R5-21-20210129","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40291-017-0279-7","article-title":"Genetic counselling for maternally inherited mitochondrial disorders","volume":"21","author":"Poulton","year":"2017","journal-title":"Mol Diagn Ther"},{"key":"R6-21-20210129","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1212\/WNL.0b013e318294b44c","article-title":"Phenotypic heterogeneity of the 8344A\u200a>\u200aG mtDNA \u201cMERRF\u201d mutation","volume":"80","author":"Mancuso","year":"2013","journal-title":"Neurology"},{"key":"R7-21-20210129","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s13311-013-0216-3","article-title":"Treatment of myoclonus","volume":"11","author":"Caviness","year":"2014","journal-title":"Neurotherapeutics"},{"key":"R8-21-20210129","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1196\/annals.1293.023","article-title":"Mitochondrial encephalomyopathies: therapeutic approach","volume":"1011","author":"Dimauro","year":"2004","journal-title":"Ann NY Acad Sci"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00029330-201903050-00021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T12:13:59Z","timestamp":1612008839000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00029330-201903050-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,5]]},"references-count":8,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000000042","relation":{},"ISSN":["0366-6999"],"issn-type":[{"value":"0366-6999","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3,5]]}}}